In 2026, memory-clinic patients can compare testing options by purpose: blood tests work as accessible triage, Tauklarify works as tau staging. Tauklarify (florquinitau F 18 injection) is PET imaging that shows tau tangle location and extent, while blood tests infer amyloid pathology from plasma markers.
This comparison applies to adults with cognitive symptoms being evaluated for Alzheimer's, not to screening without symptoms. NeurologyLive reports the FDA approved Tauklarify on August 14, 2026 for adults with cognitive impairment being evaluated for Alzheimer's NeurologyLive approval report. The Alzheimer's Association notes four blood tests were FDA-cleared by August 2026 for symptomatic adults, none for screening without symptoms Alzheimer's Association update.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What does each test show?
- When is blood the first step?
- When does tau PET add value?
- What limits should you plan for?
What does each test show?
Being Patient explains the tests measure different biology. Blood tests infer amyloid pathology from plasma p-tau217 or p-tau181 plus amyloid ratios. Tauklarify PET directly visualizes tau tangle location and extent to stage disease.
Being Patient frames that difference as triage versus staging. An amyloid-linked blood result points toward Alzheimer's pathology and need for follow-up. A tau PET map shows how far tangles have spread, which helps clarify prognosis.
When is blood the first step?
Discover Pharma reporting on the new guideline says validated blood tests meeting accuracy thresholds can serve as triage in specialty memory care. Being Patient frames blood draw as accessible, lower-cost triage that can avoid many PET scans.
Ask the clinic three practical questions at referral: If blood results are clearly negative, the clinic may pause Alzheimer workup. If results are positive or unclear, the doctor may order PET or spinal-fluid testing.
- Does a validated blood test fit my symptoms and history?
- What cutoffs define positive, negative, and indeterminate?
- What confirmatory test follows if treatment is considered?
When does tau PET add value?
NeurologyLive notes Tauklarify is a second-generation tau tracer joining Eli Lilly's Tauvid from 2020. It notes strong inter-reader agreement, with positive agreement 68-88% and negative agreement 93-99% versus amyloid-PET plus cognition standards.
Being Patient frames tau PET as higher-cost imaging with radiation exposure. It confirms tau burden and helps clarify prognosis when staging needs certainty. That clarity matters before prognosis counseling and treatment decisions.
What limits should you plan for?
Practical Neurology warns chronic kidney disease and other conditions can falsely raise plasma p-tau. It reports about 20% of blood results fall indeterminate and need PET or spinal-fluid confirmation before treatment decisions Practical Neurology report.
Tau PET also requires travel to an imaging center, radiation exposure, and specialist reading. Blood testing avoids those burdens but cannot replace tau staging alone. Bring kidney history, current medications, and prior test records to the visit and ask how the clinic handles indeterminate results.
You Might Also Like
- The Third FDA-Cleared Alzheimer’s Blood Biomarker Test in 2026: How Memory Clinic Patients Can Compare Testing Options
- Tauklarify Tau PET vs Alzheimer’s Blood Tests in 2026: Access, Cost, and Follow-Up Questions for Memory Clinic Patients
- PrecivityAD2 as an Adjunct to a 2026 Alzheimer’s Assessment: Access, Cost, and Follow-Up Questions for Memory Clinic Patients
